CiVi Biopharma Holding Corp. is a clinical-stage research and development biotechnology company whose mission is to create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company has multiple assets in various stages of development. Through its wholly-owned subsidiary, Eicos Sciences, Inc., CiVi Biopharma is developing Intravenous Iloprost for the treatment of severe frostbite. In addition, CiVi is conducting Non-Human Primate trials of CiVi 008, a next-generation oral PCSK9, for the treatment and prevention of cardiovascular disease. Founded in 2017, by Chief Scientific Officer, Henrik Oerum, and led by Chief Executive Officer, Shal Jacobovitz, the company is headquartered in Chevy Chase, MD.